Multiple actuations of salbutamol MDI into a spacer device reduce the amount of drug recovered in the respirable range

P.W. Barry, C. O'Callaghan

ABSTRACT: We wanted to determine the amount of salbutamol available in respirable particles from the Volumatic® spacer device after one, two or five actuations of a metered-dose inhaler into the spacer prior to analysis. A glass multistage liquid impinger was used to determine particle size. Aerosol was sampled after one, two or five actuations from a metered-dose inhaler into a Volumatic® spacer. Each experiment was repeated four times.

The amount of salbutamol recovered per actuation in particles less than 5 µm (mean and 95% confidence intervals) was: 54.3 µg (48.3–60.1) after one actuation; 42.4 µg (38.2–46.5) after two actuations, and 20.7 µg (17.5–23.9) after five actuations.

We conclude that multiple actuations of salbutamol into the Volumatic® spacer do not linearly increase the amount of drug available for inhalation. To maximize drug delivery, single actuations should be used prior to inhalation. In comparative studies of drugs and dosages, it must be remembered that the amount of drug delivered is not the same as that administered.

Methods

A glass multistage liquid impinger (MSLI), as modified by Bell et al [4] was used to determine the MDI output under different conditions. The MSLI operates by drawing an aerosol through a series of stages, each containing a glass impaction plate. Aerosol velocity increases in the device and progressively smaller particles collect at each stage. A filter after the final stage collects the smallest particles. Each stage was washed with methanol, and the amount of drug collected in each stage was assayed by high performance liquid chromatography with an ultra-violet detector at a wavelength of 276 nm.

A standard MDI of salbutamol (Allen & Hanburys, 100 µg per actuation) was shaken for 10 s, connected to the MSLI and discharged into it. This was repeated 10 times to facilitate the drug assay.

The experiment was repeated using the Volumatic® spacer. The MDI was shaken and then actuated into the spacer. This was immediately attached to the MSLI. To assess the effect of multiple actuations into the spacer, the MDI was actuated into the spacer one, two or five times prior to attaching it to the MSLI. For each of the experiments, the aerosol was actuated a total of 10 times. Before each actuation, the MDI was shaken for 10 s. Five new metered-dose inhalers were used. The first 10 doses from each were discarded, and the metered dose-inhaler primed by firing one shot to waste prior to each experiment.

Each experiment was repeated four times, and the temperature, relative humidity and barometric pressure were recorded. The size distribution of the aerosol cloud was...
determined from the amount of drug recovered from each stage; the MSLI having been previously calibrated with an aerosol of known particle size distribution operating under the same conditions as in this experiment.

**Results**

Particles smaller than 5 µm are thought to enter the respiratory tract (the respirable range). We report on the amount of drug contained in particles smaller than 5 and 3 µm, the mass median aerodynamic diameter (MMAD) and the geometric standard deviation (GSD) [5] for each experiment. The amount of drug recovered (mean and 95% confidence intervals), the MMAD and GSD for the different experiments are given in table 1.

Mean temperature was 23.1°C (range 21–25°C), mean barometric pressure was 1005 mmHg (range 998–1014 mmHg) and the mean relative humidity was 56% (range 47–65%).

Use of the Volumatic spacer increased the amount of salbutamol available for inhalation by 17 and 30% in particles less than 5 and 3 µm, respectively. Multiple actuations decreased drug recovery per 100 µg actuation by 22% (2 actuations) and 62% (5 actuations) for particles less than 5 µg compared with single actuations. Thus, when five 100 µg actuations were released into the spacer before inhalation, only 103 µm were recovered in particles smaller than 5 µm. If the same number of actuations had been administered with an inhalation between each one, 270 µg would have been recovered.

**Discussion**

Multiple actuations of salbutamol 100 µg·actuation⁻¹ into the Volumatic spacer decrease the amount of drug present in particles within the respirable range. In these circumstances, dose delivered is not the same as dose administered. This is important where the dose delivered needs to be high, as in the treatment of an exacerbation of asthma, and where the dose delivered needs to be precisely known, for instance in comparative studies of the effects of different drugs.

Current British Thoracic Society guidelines suggest the administration of two puffs of bronchodilator into a spacer device prior to inhalation in the emergency treatment of asthma in adults, where a nebulizer is not available [2]. Administering each puff separately would increase the amount of drug available for inhalation by over 20%. Previous guidelines recommended inhalation after multiples of five puffs, reducing respirable drug delivery by almost two thirds [6].

If spacers are used in studies of dosimetry, conclusions on dose-equivalence and dose response may be made from an incorrect assumption of dose delivered. In a recent study, the dose equivalence of salmeterol and salbutamol in patients with asthma was determined [3]. Salmeterol was delivered by multiples of five actuations into a Volumatic spacer prior to inhalation, and salmeterol by metered-dose inhaler without a spacer. It was estimated that 50 µg of salmeterol was equivalent to up to 500 µg of salbutamol. Our study suggests that administering 500 µg of salbutamol in the way described delivers only the same amount of respirable drug as two separate 100 µg actuations.

The present study confirms our earlier work and that of others into multiple dosing into spacer devices with sodium cromoglycate [5, 7, 8], and nedocromil sodium [9]. Multiple actuations of the MDI may decrease the amount of respirable drug recovered because of agglomeration of particles increasing their size, displacement of aerosol out of the spacer or onto the spacer walls, or the electrostatic attraction of particles to the spacer and each other. As different drug formulations and spacer devices have different physical and electrostatic properties, findings of one study may not be applicable to other drugs and devices.

For the administration of salbutamol use of the Volumatic spacer device increases the amount of drug available for inhalation in respirable particles provided that multiple actuations into the Volumatic are avoided.

---

**Table 1. – The effect of different methods of use of the Volumatic spacer on the delivery of salbutamol**

<table>
<thead>
<tr>
<th>Method of delivery</th>
<th>Salbutamol recovered (µg) per 100 µg actuation</th>
<th>Dose to patient</th>
<th>In particles ≤5 µm</th>
<th>In particles ≤3 µm</th>
<th>MMAD µm</th>
<th>GSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct from metered-dose inhalers</td>
<td>90.5 (81.4–99.6)</td>
<td>46.3 (36.3–56.3)</td>
<td>34.4 (27.5–41.3)</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Via Volumatic spacer:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 actuation</td>
<td>62.1 (56.0–68.2)</td>
<td>54.3 (48.3–60.1)</td>
<td>44.9 (39.0–50.8)</td>
<td>1.74 (1.57–1.90)</td>
<td>2.41 (2.30–2.51)</td>
<td></td>
</tr>
<tr>
<td>2 actuations</td>
<td>49.7 (45.9–53.4)</td>
<td>42.4 (38.2–46.5)</td>
<td>34.9 (31.1–38.8)</td>
<td>1.75 (1.21–2.30)</td>
<td>2.92 (1.98–3.85)</td>
<td></td>
</tr>
<tr>
<td>3 actuations</td>
<td>22.7 (18.7–26.7)</td>
<td>20.7 (17.5–23.9)</td>
<td>17.5 (14.9–20.1)</td>
<td>1.61 (1.47–1.75)</td>
<td>2.27 (2.09–2.45)</td>
<td></td>
</tr>
</tbody>
</table>

Data are presented as mean and 95% confidence interval in parenthesis, MMAD: mass median aerodynamic diameter; GSD: geometric standard deviation.
References